STABILIZATION OF QUINOL COMPOSITION SUCH AS CATECHOLAMINE DRUGS
First Claim
Patent Images
1. A stable pharmaceutical formulation, comprising:
- (a) a first composition that comprises at least one quinol compound having a first desired pharmacological activity;
(b) a second composition that comprises at least one local anesthetic compound, said local anesthetic compound comprising at least one amine group that is capable of being reversibly protonated, and being capable of reversibly binding to a voltage-gated Na+ channel in a cell membrane to thereby after Na+ movement through the voltage-gated Na+ channel;
(c) at least one thiol agent; and
(d) at least one pH buffer that maintains a substantially constant pH in the pharmaceutical formulation, wherein the pH is greater than about pH 5.5.
0 Assignments
0 Petitions
Accused Products
Abstract
Compositions and methods are provided for obtaining stabilized quinol compositions, such as catecholamine drugs (e.g., epinephrine solutions), and also for obtaining stable pharmaceutical formulations that comprise a stabilized quinol composition and a second pharmacologically active component such as a local anesthetic or other active drug ingredient having a reversibly protonated amine group. Stability is achieved through the inclusion of an appropriately selected pH buffer and a thiol agent, based on redox and pH buffering principles including pKa of the buffer and of the reversibly protonated amine group.
23 Citations
54 Claims
-
1. A stable pharmaceutical formulation, comprising:
-
(a) a first composition that comprises at least one quinol compound having a first desired pharmacological activity; (b) a second composition that comprises at least one local anesthetic compound, said local anesthetic compound comprising at least one amine group that is capable of being reversibly protonated, and being capable of reversibly binding to a voltage-gated Na+ channel in a cell membrane to thereby after Na+ movement through the voltage-gated Na+ channel; (c) at least one thiol agent; and (d) at least one pH buffer that maintains a substantially constant pH in the pharmaceutical formulation, wherein the pH is greater than about pH 5.5. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 45, 46, 47, 48, 49, 50)
-
-
42. A stable pharmaceutical formulation, comprising:
-
(a) a first composition that comprises at least one quinol compound having a first desired pharmacological activity; (b) a second composition that comprises at least one local anesthetic compound that is capable of reversibly binding to a voltage-gated Na+ channel in a cell membrane to thereby after Na+ movement through the voltage-gated Na+ channel; (c) at least one thiol agent; and (d) at least one pH buffer that maintains a substantially constant pH in the pharmaceutical formulation, wherein the pH is greater than about pH 5.5. - View Dependent Claims (43, 44)
-
-
51. A method of stabilizing a pharmaceutical formulation, comprising:
-
contacting (a) a pharmaceutical formulation, (b) at least one thiol agent, and (c) a pH buffer that maintains a substantially constant pH, wherein the pH is greater than about pH 5.5, wherein; the pharmaceutical formulation of (a) comprises (i) a first composition that comprises at least one quinol compound having a first desired pharmacological activity, and (ii) a second composition that comprises at least one local anesthetic compound, said local anesthetic compound comprising an amine-containing compound having a second desired pharmacological activity and at least one amine group that is capable of being reversibly protonated, and thereby stabilizing the pharmaceutical formulation.
-
-
52. A method of stabilizing a pharmaceutical formulation, comprising:
contacting (a) a pharmaceutical formulation which comprises (i) a first composition that comprises at least one quinol compound having a first desired pharmacological activity, and (ii) a second composition that comprises at least one local anesthetic compound, said local anesthetic compound comprising an amine-containing compound having a second desired pharmacological activity and at least one amine group that is capable of being reversibly protonated, (b) at least one thiol agent, and (c) a pH buffer that maintains a substantially constant pH, to produce a stable pharmaceutical formulation.
-
53. A method of treating a subject, comprising administering to said subject a stable pharmaceutical formulation, comprising:
-
(a) a first composition that comprises at least one quinol compound having a first desired pharmacological activity; (b) a second composition that comprises at least one local anesthetic compound, said local anesthetic compound comprising an amine-containing compound having a second desired pharmacological activity and at least one amine group that is capable of being reversibly protonated; (c) at least one thiol agent; and (d) at least one pH buffer that maintains a substantially constant pH in the pharmaceutical formulation, wherein the pH is greater than about pH 5.5.
-
-
54. A method for the manufacture of a medicament for therapeutic treatment of a subject with a stable pharmaceutical formulation, said method comprising:
-
contacting (a) a pharmaceutical formulation, (b) at least one thiol agent, and (c) a pH buffer that maintains a substantially constant pH, wherein the pH is greater than about pH 5.5, wherein; the pharmaceutical formulation of (a) comprises (i) a first composition that comprises at least one quinol compound having a first desired pharmacological activity, and (ii) a second composition that comprises at least one local anesthetic compound, said local anesthetic compound comprising an amine-containing compound having a second desired pharmacological activity and at least one amine group that is capable of being reversibly protonated.
-
Specification